Trevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The ...

I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called ...

Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments. The biopharmaceutical company posted a loss of $11.4 million, or 11 cents ...

Trevi had three positive and meaningful clinical data read-outs over the past few months validating the strategy of developing Haduvio as a ...

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) had its price target cut by stock analysts at Needham & Company LLC from ...

In a recent, cross-institutional study, researchers report that healthy human airways are at higher risk for dehydration and ...

In a recent, cross-institutional study partially funded by the National Institutes of Health, researchers report that healthy human airways are at higher risk for dehydration and inflammation when ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has been assigned an average recommendation of “Buy” from the ten ...

In a recent, cross-institutional study partially funded by the National Institutes of Health, researchers report that healthy ...

I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called mycobacterium avium complex. Would you kindly consider discussing this?

Kyorin Pharma has signed a deal with digital health firm Hyfe to develop a digital therapeutic (DTx) for people with chronic cough and launch it in Japan. Hyfe's platform uses artificial ...